{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T18:53:57Z","timestamp":1740164037404,"version":"3.37.3"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T00:00:00Z","timestamp":1697673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T00:00:00Z","timestamp":1697673600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100013500","name":"Diabetestutkimuss\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013500","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Effective treatment may prevent kidney complications, but women might be underprescribed. Novel, data-driven insights into prescriptions and their relationship with kidney health in women with type 1 diabetes may help to optimize treatment. We identified six medication profiles in 1164 women from the FinnDiane Study with normal albumin excretion rate based on clusters of their baseline prescription data using a self-organizing map. Future rapid kidney function decline was defined as an annual estimated glomerular filtration rate (eGFR) loss\u2009&gt;\u20093\u00a0ml\/min\/1.73\u00a0m<jats:sup>2<\/jats:sup> after baseline. Two profiles were associated with future decline: Profile <jats:italic>ARB<\/jats:italic> with the highest proportion of angiotensin receptor blockers (odds ratio [OR] 2.75, <jats:italic>P<\/jats:italic>\u2009=\u20090.02) and highly medicated women in profile <jats:italic>HighMed<\/jats:italic> (OR 2.55, <jats:italic>P<\/jats:italic>\u2009=\u20090.03). Compared with profile <jats:italic>LowMed<\/jats:italic> (low purchases of all)<jats:italic>,<\/jats:italic> profile <jats:italic>HighMed<\/jats:italic> had worse clinical characteristics, whereas in profile <jats:italic>ARB<\/jats:italic> only systolic blood pressure was elevated. Importantly, the younger women in profile <jats:italic>ARB<\/jats:italic> with fewer kidney protective treatments developed a rapid decline despite otherwise similar baseline characteristics to profile <jats:italic>ACE &amp; Lipids<\/jats:italic> (the highest proportions of ACE inhibitors and lipid-modifying agents) without a future rapid decline. In conclusion, medication profiles identified different future eGFR trajectories in women with type 1 diabetes revealing potential treatment gaps for younger women.<\/jats:p>","DOI":"10.1038\/s41598-023-44695-2","type":"journal-article","created":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T17:01:52Z","timestamp":1697734912000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Medication profiling in women with type 1 diabetes highlights the importance of adequate, guideline-based treatment in low-risk groups"],"prefix":"10.1038","volume":"13","author":[{"given":"Raija","family":"Lithovius","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Mutter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika B.","family":"Parente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ville-Petteri","family":"M\u00e4kinen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erkka","family":"Valo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valma","family":"Harjutsalo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Per-Henrik","family":"Groop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,10,19]]},"reference":[{"key":"44695_CR1","doi-asserted-by":"publisher","first-page":"380","DOI":"10.4239\/wjd.v6.i3.380","volume":"6","author":"KM Simmons","year":"2015","unstructured":"Simmons, K. M. & Michels, A. W. Type 1 diabetes: A predictable disease. World J. Diabetes 6, 380\u2013390 (2015).","journal-title":"World J. Diabetes"},{"key":"44695_CR2","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S2213-8587(22)00099-7","volume":"10","author":"F Jansson Sigfrids","year":"2022","unstructured":"Jansson Sigfrids, F., Groop, P.-H. & Harjutsalo, V. Incidence rate patterns, cumulative incidence, and time trends for moderate and severe albuminuria in individuals diagnosed with type 1 diabetes aged 0\u201314 years: A population-based retrospective cohort study. Lancet Diabetes Endocrinol. 10, 489\u2013498 (2022).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"44695_CR3","doi-asserted-by":"publisher","first-page":"164","DOI":"10.2337\/diacare.28.1.164","volume":"28","author":"JL Gross","year":"2005","unstructured":"Gross, J. L. et al. Diabetic nephropathy: Diagnosis, prevention, and treatment. Diabetes Care 28, 164\u2013176 (2005).","journal-title":"Diabetes Care"},{"key":"44695_CR4","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s40620-014-0077-9","volume":"27","author":"E Cohen","year":"2014","unstructured":"Cohen, E. et al. A longitudinal assessment of the natural rate of decline in renal function with age. J. Nephrol. 27, 635\u2013641 (2014).","journal-title":"J. Nephrol."},{"key":"44695_CR5","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1016\/j.kint.2017.11.024","volume":"93","author":"N Nowak","year":"2018","unstructured":"Nowak, N. et al. Markers of early progressive renal decline in type 2 diabetes suggest different implications for etiological studies and prognostic tests development. Kidney Int. 93, 1198\u20131206 (2018).","journal-title":"Kidney Int."},{"key":"44695_CR6","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1093\/ndt\/gfv121","volume":"30","author":"P Bjornstad","year":"2015","unstructured":"Bjornstad, P. et al. Rapid GFR decline is associated with renal hyperfiltration and impaired GFR in adults with Type 1 diabetes. Nephrol. Dial. Transplant. 30, 1706\u20131711 (2015).","journal-title":"Nephrol. Dial. Transplant."},{"key":"44695_CR7","doi-asserted-by":"publisher","first-page":"748","DOI":"10.2337\/dc17-1618","volume":"41","author":"P-H Groop","year":"2018","unstructured":"Groop, P.-H. et al. Excess mortality in patients with type 1 diabetes without albuminuria-separating the contribution of early and late risks. Diabetes Care 41, 748\u2013754 (2018).","journal-title":"Diabetes Care"},{"key":"44695_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001321","volume":"9","author":"SJ Livingstone","year":"2012","unstructured":"Livingstone, S. J. et al. Risk of cardiovascular disease and total mortality in adults with type 1 diabetes: Scottish registry linkage study. PLoS Med. 9, e1001321 (2012).","journal-title":"PLoS Med."},{"key":"44695_CR9","first-page":"77","volume":"10","author":"SS Roscioni","year":"2014","unstructured":"Roscioni, S. S., Heerspink, H. J. & de Zeeuw, D. The effect of RAAS blockade on the progression of diabetic nephropathy. Nat. Rev. 10, 77\u201387 (2014).","journal-title":"Nat. Rev."},{"key":"44695_CR10","first-page":"448","volume":"71","author":"F Waanders","year":"2013","unstructured":"Waanders, F., Visser, F. W. & Gans, R. O. Current concepts in the management of diabetic nephropathy. Neth. J. Med. 71, 448\u2013458 (2013).","journal-title":"Neth. J. Med."},{"key":"44695_CR11","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/1475-2840-12-78","volume":"12","author":"A Kautzky-Willer","year":"2013","unstructured":"Kautzky-Willer, A. et al. Sex-specific-differences in cardiometabolic risk in type 1 diabetes: A cross-sectional study. Cardiovasc. Diabetol. 12, 78 (2013).","journal-title":"Cardiovasc. Diabetol."},{"key":"44695_CR12","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1111\/j.1464-5491.2010.02972.x","volume":"27","author":"ME Larkin","year":"2010","unstructured":"Larkin, M. E. et al. Disparity in management of diabetes and coronary heart disease risk factors by sex in DCCT\/EDIC. Diabetes Med. J. Br. Diabet. Assoc. 27, 451\u2013458 (2010).","journal-title":"Diabetes Med. J. Br. Diabet. Assoc."},{"key":"44695_CR13","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2337\/dc07-1244","volume":"31","author":"A Ferrara","year":"2008","unstructured":"Ferrara, A. et al. Sex disparities in control and treatment of modifiable cardiovascular disease risk factors among patients with diabetes: Translating Research Into Action for Diabetes (TRIAD) Study. Diabetes Care 31, 69\u201374 (2008).","journal-title":"Diabetes Care"},{"key":"44695_CR14","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S2213-8587(14)70248-7","volume":"3","author":"RR Huxley","year":"2015","unstructured":"Huxley, R. R., Peters, S. A., Mishra, G. D. & Woodward, M. Risk of all-cause mortality and vascular events in women versus men with type 1 diabetes: A systematic review and meta-analysis. Lancet Diabetes Endocrinol. 3, 198\u2013206 (2015).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"44695_CR15","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/S2213-8587(21)00172-8","volume":"9","author":"V Harjutsalo","year":"2021","unstructured":"Harjutsalo, V., Pongrac Barlovic, D. & Groop, P.-H. Long-term population-based trends in the incidence of cardiovascular disease in individuals with type 1 diabetes from Finland: A retrospective, nationwide, cohort study. Lancet Diabetes Endocrinol. 9, 575\u2013585 (2021).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"44695_CR16","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1097\/MED.0000000000000074","volume":"21","author":"P Bjornstad","year":"2015","unstructured":"Bjornstad, P. Early diabetic nephropathy in type 1 diabetes: New insights. Curr. Opin. Endocrinol. Diabetes 21, 279\u2013286 (2015).","journal-title":"Curr. Opin. Endocrinol. Diabetes"},{"key":"44695_CR17","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1093\/ndt\/gfu411","volume":"31","author":"GC Chan","year":"2016","unstructured":"Chan, G. C. & Tang, S. C. Diabetic nephropathy: Landmark clinical trials and tribulations. Nephrol. Dial. Transplant. 31, 359\u2013368 (2016).","journal-title":"Nephrol. Dial. Transplant."},{"key":"44695_CR18","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1093\/ije\/dyy113","volume":"48","author":"S Gao","year":"2018","unstructured":"Gao, S., Mutter, S., Casey, A. & M\u00e4kinen, V. P. Numero: A statistical framework to define multivariable subgroups in complex population-based datasets. Int. J. Epidemiol. 48, 369\u2013374. https:\/\/doi.org\/10.1093\/ije\/dyy113 (2018).","journal-title":"Int. J. Epidemiol."},{"key":"44695_CR19","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.2337\/diacare.28.8.2019","volume":"28","author":"LM Thorn","year":"2005","unstructured":"Thorn, L. M. et al. Metabolic syndrome in type 1 diabetes: Association with diabetic nephropathy and glycemic control (the FinnDiane study). Diabetes Care 28, 2019\u20132024 (2005).","journal-title":"Diabetes Care"},{"key":"44695_CR20","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1007\/s00125-018-4564-8","volume":"61","author":"FJ Jansson","year":"2018","unstructured":"Jansson, F. J. et al. Regression of albuminuria and its association with incident cardiovascular outcomes and mortality in type 1 diabetes: The FinnDiane Study. Diabetologia 61, 1203\u20131211 (2018).","journal-title":"Diabetologia"},{"issue":"Suppl 1","key":"44695_CR21","first-page":"S79","volume":"27","author":"ME Molitch","year":"2004","unstructured":"Molitch, M. E. et al. Nephropathy in diabetes. Diabetes Care 27(Suppl 1), S79-83 (2004).","journal-title":"Diabetes Care"},{"key":"44695_CR22","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.2337\/dc20-S002","volume":"43","author":"American Diabetes Association","year":"2020","unstructured":"American Diabetes Association. Classification and diagnosis of diabetes: Standards of medical care in diabetes-2020. Diabetes Care 43, S14\u2013S31 (2020).","journal-title":"Diabetes Care"},{"key":"44695_CR23","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey, A. S. et al. A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 150, 604\u2013612 (2009).","journal-title":"Ann. Intern. Med."},{"key":"44695_CR24","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology, N., Oslo. ATC\/DDD Index. https:\/\/www.whocc.no\/atc_ddd_index\/"},{"key":"44695_CR25","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1007\/s00125-017-4273-8","volume":"60","author":"R Lithovius","year":"2017","unstructured":"Lithovius, R. et al. Data-driven metabolic subtypes predict future adverse events in individuals with type 1 diabetes. Diabetologia 60, 1234\u20131243 (2017).","journal-title":"Diabetologia"},{"key":"44695_CR26","doi-asserted-by":"publisher","first-page":"2480","DOI":"10.2337\/db08-0332","volume":"57","author":"VP M\u00e4kinen","year":"2008","unstructured":"M\u00e4kinen, V. P. et al. Metabolic phenotypes, vascular complications, and premature deaths in a population of 4,197 patients with type 1 diabetes. Diabetes 57, 2480\u20132487 (2008).","journal-title":"Diabetes"},{"key":"44695_CR27","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1021\/pr201036j","volume":"11","author":"VP M\u00e4kinen","year":"2012","unstructured":"M\u00e4kinen, V. P. et al. Metabolic diversity of progressive kidney disease in 325 patients with type 1 diabetes (the FinnDiane Study). J. Proteome Res. 11, 1782\u20131790 (2012).","journal-title":"J. Proteome Res."},{"key":"44695_CR28","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.3390\/nu9101153","volume":"9","author":"S Mutter","year":"2017","unstructured":"Mutter, S., Casey, A. E., Zhen, S., Shi, Z. & M\u00e4kinen, V. P. Multivariable analysis of nutritional and socio-economic profiles shows differences in incident anemia for northern and southern Jiangsu in China. Nutrients 9, 1153. https:\/\/doi.org\/10.3390\/nu9101153 (2017).","journal-title":"Nutrients"},{"key":"44695_CR29","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/S0304-3800(01)00324-6","volume":"146","author":"JL Giraudel","year":"2001","unstructured":"Giraudel, J. L. & Lek, S. A. Comparison of self-organizing map algorithm and some conventional statistical methods for ecological community ordination. Ecol. Model. 146, 329\u2013339 (2001).","journal-title":"Ecol. Model."},{"key":"44695_CR30","unstructured":"Team, R. C. R: A Language and Environment for Statistical Computing (R Foundation for Statistical Computing, 2019). http:\/\/www.R-project.org\/."},{"key":"44695_CR31","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.024199","volume":"11","author":"D Banco","year":"2022","unstructured":"Banco, D. et al. Sex and race differences in the evaluation and treatment of young adults presenting to the emergency department with chest pain. J. Am. Heart Assoc. 11, e024199 (2022).","journal-title":"J. Am. Heart Assoc."},{"key":"44695_CR32","doi-asserted-by":"publisher","first-page":"S145","DOI":"10.1681\/ASN.2005121320","volume":"17","author":"R Trevisan","year":"2006","unstructured":"Trevisan, R., Dodesini, A. R. & Lepore, G. Lipids and renal disease. J. Am. Soc. Nephrol. JASN 17, S145-147 (2006).","journal-title":"J. Am. Soc. Nephrol. JASN"},{"key":"44695_CR33","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1046\/j.1523-1755.2003.00164.x","volume":"64","author":"AJ Jenkins","year":"2003","unstructured":"Jenkins, A. J. et al. Lipoproteins in the DCCT\/EDIC cohort: Associations with diabetic nephropathy. Kidney Int. 64, 817\u2013828 (2003).","journal-title":"Kidney Int."},{"key":"44695_CR34","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/ki.2012.189","volume":"82","author":"J Skupien","year":"2012","unstructured":"Skupien, J. et al. The early decline in renal function in patients with type 1 diabetes and proteinuria predicts the risk of end-stage renal disease. Kidney Int. 82, 589\u2013597 (2012).","journal-title":"Kidney Int."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-44695-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-44695-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-44695-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T09:19:39Z","timestamp":1700385579000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-44695-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,19]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["44695"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-44695-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2023,10,19]]},"assertion":[{"value":"23 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.-H.G. has received lecture honoraria from Astellas, Astra Zeneca, Bayer, Boehringer Ingelheim, Eli Lilly, EloWater, Genzyme, Medscape, MSD, Mundipharma, Novartis, Novo Nordisk, Peer Voice, Sanofi and Sciarc. P-H.G. is an advisory board member for AbbVie, Astellas, Astra Zeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Medscape, MSD, Mundipharma, Novartis, Novo Nordisk, and Sanofi. P-H.G. has received investigator-initiated grants from Eli Lilly and Roche. E.B.P. reports receiving lecture honorariums from Eli Lilly, Abbott, Astra Zeneca, Sanofi, and Boehringer Ingelheim and is an advisory board member of Sanofi. No other potential conflicts of interest relevant to this article were reported. The funding sources were not involved in the design or conduct of the study. All other authors declare that there is no duality of interest associated with this manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17893"}}